HER kinase inhibitors are permitted for post‐line treatment and subsequent adjuvant therapy of HER2‐positive breast cancer and first‐line therapy of HER2‐positive, HR‐positive breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.